The Problem of Ill-Gotten Gain in Health Care
C. Ben Mitchell, Ph.D. Distinguished Fellow
The politicized debate about President Trump’s treatment for Covid-19 may have shrouded an important set of questions about the science of developing treatments, viz., the problem of ill-gotten gain.
Among other treatment protocols, the President received Regeneron’s REGN-COV2, a “cocktail” of two neutralizing antibodies that has shown promise in some animal studies (see here and here). The media jumped on an association between REGN-COV2 antibodies and fetal cells, some even claiming that the antibodies were developed from fetal cells.
Screenshot of NYT headline on Oct. 8, 2020
The fact of the matter is REGN-COV2 was tested for its virus-neutralizing ...read more
The Problem of Ill-Gotten Gain in Health Care Read More »